Trial Profile
Efficacy and safety of Sofosbuvir/Velpatasvir/Voxilaprevir in Chronic Hepatitis C infected patients with Prior Treatment Failures with Glecaprevir/Pibrentasvir
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 May 2019
Price :
$35
*
At a glance
- Drugs Sofosbuvir/velpatasvir/voxilaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 08 May 2019 Results published in the American Journal of Gastroenterology
- 10 Dec 2018 New trial record
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases